Thalidomide Pharmion-Important Safety Information from Celgene as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 01/08/2008

Problem Or Issue:
Please find herewith an important safety communication from Celgene to draw attention to the potential risks of treatment with Thalidomide Pharmion, including the risk of teratogenicity, and to explain how you must follow the Thalidomide Pharmion PPP in order to obtain and dispense Thalidomide Pharmion appropriately

« Back